A Discussion on oHCM: Part 2 – How Pharmacists Can Confidently Manage Mavacamten Therapy

In the second part of an interview with Pharmacy Times, Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, a cardiovascular clinical pharmacist with Baptist Health System and the University of Kentucky College of Pharmacy, discussed how real-world Risk Evaluation and Mitigation Strategy (REMS) data for mavacamten (Camzyos; Bristol Myers Squibb) reinforces confidence in the drug’s monitoring protocols—and why the program’s structure represents a distinctive opportunity for pharmacist engagement in the management of obstructive hypertrophic cardiomyopathy (oHCM).

Beavers framed his perspective specifically through the lens of pharmacy practice, arguing that the REMS program's clearly outlined dosing and titration structure—anchored primarily in echocardiographic monitoring of left ventricular outflow tract gradient—makes mavacamten particularly well-suited for pharmacist involvement. Unlike many complex cardiovascular therapies where monitoring parameters can be multifaceted and difficult to standardize, mavacamten's titration decisions are guided by a consistent, measurable end point that pharmacists can readily learn and apply in collaboration with cardiologists.

Beavers emphasized that the low rate of clinically meaningful drug-drug interactions observed in real-world REMS data further supports confidence in the protocol, reinforcing that when the program's guidelines are followed carefully, mavacamten can be managed safely and effectively. He noted that the clarity and consistency of the monitoring framework removes much of the ambiguity that can make pharmacist-led titration feel daunting in other therapeutic areas.

His overarching message was one of empowerment: pharmacists who invest in learning the language of OCHM management—understanding what to look for on echocardiography reports and how to apply titration criteria—can play a meaningful, confident role in this space. Building pharmacy protocols and workflows around the existing REMS structure, he argued, is the key to unlocking that potential and strengthening the pharmacist-cardiologist partnership in managing this patient population.